SCHEMBL6929138

SCHEMBL6929138

Clc1ccc(-c2c[nH]c(-c3ccc(N4CCNCC4)nc3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.46
CNR2 P34972 2/20 0.46
HTR3A P46098 5/20 0.45
HTR3E A5X5Y0 3/20 0.45
HTR3B O95264 3/20 0.45
HTR3D Q70Z44 3/20 0.45
HTR3C Q8WXA8 3/20 0.45
HTR1A P08908 3/20 0.43
HTR7 P34969 2/20 0.43
HTR2B P41595 2/20 0.43
HTR6 P50406 2/20 0.43
HTR2A P28223 2/20 0.43
HTR5A P47898 1/20 0.43
RET P07949 3/20 0.43
GPR119 Q8TDV5 1/20 0.43
MAP3K11 Q16584 1/20 0.43
KCNH2 Q12809 1/20 0.42
CACNA1C Q13936 1/20 0.42
ASIC3 Q9UHC3 1/20 0.42
ADRB1 P08588 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924500 0.89 ATR (0.51) CNR2HTR3AHTR3EHTR3BHTR3D
SCHEMBL6920358 0.88 CNR2 (0.52) CNR2HTR3AHTR3EHTR3BHTR3D
SCHEMBL6924654 0.88 HDAC1 (0.50) HTR3AHTR1AHTR7HTR2BHTR6
SCHEMBL6927440 0.86 HRH4 (0.51) CNR2HTR3ARETKCNH2MEN1
SCHEMBL6923696 0.83 RET (0.43) CNR2RETKCNH2KDM4E
SCHEMBL12911533 0.82 GPR119 (0.58) FAAHCNR2HTR3AHTR3EHTR3B
SCHEMBL6924156 0.82 SCN9A (0.41) GPR119MAP3K11KCNH2CACNA1CASIC3
SCHEMBL6926962 0.82 RET (0.47) CNR2RETGPR119KCNH2KMT2A
Hydrochloric Acid SCHEMBL6786143 0.81 GPR119 (0.56) FAAHCNR2HTR3AHTR3EHTR3B
Hydrochloric Acid SCHEMBL940785 0.81 GPR119 (0.56) FAAHCNR2HTR3AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R FAAH 134/4885CNR2 122/4885HTR3A 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.